Provided by Tiger Trade Technology Pte. Ltd.

Replimune Group Inc.

15.98
+0.31001.98%
Post-market: 16.000.0200+0.13%19:30 EDT
Volume:1.99M
Turnover:31.68M
Market Cap:1.51B
PE:-5.06
High:16.33
Open:15.65
Low:15.50
Close:15.67
52wk High:16.33
52wk Low:1.50
Shares:94.22M
Float Shares:77.49M
Volume Ratio:1.00
T/O Rate:2.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1550
EPS(LYR):-3.3828
ROE:-134.29%
ROA:-51.30%
PB:14.25
PE(LYR):-4.72

Loading ...

BRIEF-Replimune Gets Third Try At FDA Approval After Makary Departure- WSJ

Reuters
·
May 29

Replimune Gets Third TRY at FDA Approval After Makary Departure- WSJ

THOMSON REUTERS
·
May 29

Replimune Expected to Announce Agreement With FDA to Resubmit Its Advanced Melanoma Treatment for Approval - WSJ

THOMSON REUTERS
·
May 29

U.S. Earnings Preview: Before Market Open May 28

Dow Jones
·
May 28

Replimune Group call volume above normal and directionally bullish

TIPRANKS
·
May 21

Biotech Investors Are Tuning Out the MAHA Chaos -- Heard on the Street -- WSJ

Dow Jones
·
May 20

Makary exit may temporarily lift biotech sentiment but FDA leadership vacuum looms

Reuters
·
May 14

BUZZ-U.S. STOCKS ON THE MOVE-Nebius, US chipmakers, Assertio Holdings

Reuters
·
May 13

BUZZ-U.S. STOCKS ON THE MOVE-Tyler Technologies, Autodesk, Illumina

Reuters
·
May 13

BUZZ-Replimune, uniQure rise; FDA commissioner Makary plans to resign

Reuters
·
May 13

Trump says US FDA Commissioner Makary is out

Reuters
·
May 13

Replimune Group Shares Slip 2.9% Premarket After Nearly 22% Gain in Previous Session

THOMSON REUTERS
·
May 11

Replimune Climbs on Report of Makary's Possible Ouster From FDA

Dow Jones
·
May 09

Replimune jumps on news FDA chief behind RP1 rejection may be removed

TIPRANKS
·
May 09

BUZZ-Replimune surges after report FDA chief Makary may be ousted

Reuters
·
May 09

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:09 PM

Reuters
·
May 09

BUZZ-U.S. STOCKS ON THE MOVE-TransDigm, Rhythm Pharmaceuticals, Intel

Reuters
·
May 06

FDA Commissioner Makary defends agency's decision on Replimune's drug

Reuters
·
May 05

Replimune Shares Fall 5% After FDA Commissioner Marty Makary Defends Agency's Decision on Co's Cancer Drug

THOMSON REUTERS
·
May 05

Rpt- FDA's Makary on Replimune Says Three Indepndent Teams Arrived at the Same Conclusions - CNBC

THOMSON REUTERS
·
May 05